[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014KN02672A - - Google Patents

Info

Publication number
IN2014KN02672A
IN2014KN02672A IN2672KON2014A IN2014KN02672A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A IN 2672KON2014 A IN2672KON2014 A IN 2672KON2014A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A
Authority
IN
India
Prior art keywords
mammal
csf
ependymal cells
apoe
protective
Prior art date
Application number
Other languages
English (en)
Inventor
Beverly L Davidson
Bradley T Hyman
Original Assignee
Univ Iowa Res Found
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found, Gen Hospital Corp filed Critical Univ Iowa Res Found
Publication of IN2014KN02672A publication Critical patent/IN2014KN02672A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN2672KON2014 2012-05-18 2013-03-14 IN2014KN02672A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648801P 2012-05-18 2012-05-18
PCT/US2013/031725 WO2013172964A1 (en) 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits

Publications (1)

Publication Number Publication Date
IN2014KN02672A true IN2014KN02672A (ja) 2015-05-08

Family

ID=49584137

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2672KON2014 IN2014KN02672A (ja) 2012-05-18 2013-03-14

Country Status (12)

Country Link
US (1) US20150183850A1 (ja)
EP (1) EP2850195B1 (ja)
JP (2) JP6469000B2 (ja)
CN (2) CN112574964A (ja)
AU (1) AU2013263346B2 (ja)
BR (1) BR112014028666B1 (ja)
CA (1) CA2873890C (ja)
ES (1) ES2786078T3 (ja)
HK (1) HK1207109A1 (ja)
IN (1) IN2014KN02672A (ja)
RU (1) RU2673484C2 (ja)
WO (1) WO2013172964A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
WO2016198627A1 (en) * 2015-06-12 2016-12-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
JP7161401B2 (ja) * 2016-04-14 2022-10-26 公益財団法人神戸医療産業都市推進機構 アミロスフェロイド(aspd)様構造体及び医薬組成物
EP3458588A4 (en) 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
EP3506927A4 (en) * 2016-08-03 2020-05-06 University of South Florida REELINE COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CA3035628A1 (en) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
CN112481269A (zh) 2017-10-03 2021-03-12 普利维尔治疗公司 用于溶酶体障碍的基因疗法
JP2020537542A (ja) 2017-10-03 2020-12-24 プリベイル セラピューティクス, インコーポレーテッドPrevail Therapeutics, Inc. ライソゾーム病の遺伝子治療
WO2020112802A1 (en) * 2018-11-28 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
AU2020367437B2 (en) * 2019-10-16 2024-11-07 Cornell University Gene therapy for Alzheimer's disease
AU2021250199B2 (en) * 2020-03-31 2024-03-07 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Deuterated oxophenylarsine compound and use thereof
WO2022115535A1 (en) * 2020-11-25 2022-06-02 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6468524B1 (en) * 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
NZ555830A (en) * 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
PT1879623E (pt) * 2005-05-02 2012-12-20 Genzyme Corp Terapia génica para distúrbios da medula espinal
KR101449587B1 (ko) * 2006-09-14 2014-10-10 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
CN101754682B (zh) * 2007-05-16 2014-11-12 布里格姆妇女医院 突触核蛋白病的治疗
EP3444346B1 (en) * 2010-04-23 2022-07-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders

Also Published As

Publication number Publication date
EP2850195A4 (en) 2015-12-09
CA2873890A1 (en) 2013-11-21
AU2013263346B2 (en) 2018-08-23
US20150183850A1 (en) 2015-07-02
EP2850195B1 (en) 2020-01-22
JP2015520161A (ja) 2015-07-16
EP2850195A1 (en) 2015-03-25
JP2019031564A (ja) 2019-02-28
RU2673484C2 (ru) 2018-11-27
CN104540952A (zh) 2015-04-22
CN112574964A (zh) 2021-03-30
AU2013263346A1 (en) 2014-12-04
BR112014028666A2 (pt) 2017-06-27
JP6469000B2 (ja) 2019-02-13
HK1207109A1 (en) 2016-01-22
CA2873890C (en) 2022-12-06
WO2013172964A1 (en) 2013-11-21
RU2014151218A (ru) 2016-07-10
ES2786078T3 (es) 2020-10-08
BR112014028666B1 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
IN2014KN02672A (ja)
CA2832151C (en) Methods and compositions for treating brain diseases
MX2023007728A (es) Composiciones para el tratamiento de esclerosis lateral amiotrofica (ela).
PH12017501436A1 (en) Enhanced delivery of viral particles to the striatum and cortex
MX2016001026A (es) Metodos y composiciones para tratar enfermedades del cerebro.
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
WO2015109124A3 (en) Immunomodulatory agents
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
MX365711B (es) Administración efectiva de genes grandes por vectores aav duales.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX2015012454A (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
PH12014502274B1 (en) Anti-fcrn antibodies
EP4219727A3 (en) Products and methods for treatment of amyotrophic lateral sclerosis
MX2014004292A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
WO2015014790A3 (en) Protease variants and polynucleotides encoding same
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
MX2014002415A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
WO2013006756A3 (en) Alpha amylase variants and polynucleotides encoding same
MX2014015002A (es) Polipeptidos que tienen actividad de transgalactosilacion.
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX353911B (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014058866A3 (en) Treatment of amyotrophic lateral sclerosis
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX2019005266A (es) Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas.